Literature DB >> 8384281

Adenomatous hyperplasia of the liver as a precancerous lesion.

Y Nakanuma1, T Terada, K Ueda, S Terasaki, A Nonomura, O Matsui.   

Abstract

Adenomatous hyperplasia (AH), a hyperplastic parenchymal nodule, is detected most often through radiological and pathological observations in chronic advanced liver disease. AH can be classified into two categories: ordinary type or macroregenerative nodule (MRN) type I, and atypical type or MRN type II. Characteristically, both types contain portal tracts with portal veins and biliary elements. Ordinary AH may represent a large regenerative nodule with limited growth potential. Atypical AH shows slightly cellular and structural atypia, altered phenotypic expression, and increased proliferative activity compared to the surrounding liver. Histologic differentiation of atypical AH from well-differentiated hepatocellular carcinoma (HCC) is controversial, and generally accepted diagnostic criteria are still lacking. Atypical AH occasionally contains overt malignant foci. Histological observations and portography show that nodules of AH are supplied by portal venous blood. While AH nodules appear to be hypoperfused according to arteriographic studies, atypical AH contains small arterial branches which are abundant in contrast to the surrounding liver. The data obtained so far indicate that atypical AH may be a hepatocellular neoplasm which belongs nosologically to a gray area of neoplasm, in which overt HCC is likely to develop. It is clinically recommended that atypical AH is treated as "malignant" because of the occasional inclusion of HCC foci. For its treatment, percutaneous ethanol injection is becoming popular.

Entities:  

Mesh:

Year:  1993        PMID: 8384281     DOI: 10.1111/j.1600-0676.1993.tb00597.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  9 in total

Review 1.  Ethanol injection for the treatment of hepatic tumours.

Authors:  C Bartolozzi; R Lencioni
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

2.  Comparison of the proliferative capacity of adenomatous hyperplasia and well differentiated hepatocellular carcinoma.

Authors:  A Yamashita
Journal:  J Gastroenterol       Date:  1996-06       Impact factor: 7.527

Review 3.  Hepatic neoplasia: reflections and ruminations.

Authors:  K Aterman
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

4.  Extracellular matrix proteins, integrin receptors (VLA-beta 1, VLA-alpha 2 and VLA-alpha 5) and growth fraction in atypical macroregenerative nodules of the liver: an immunocytochemical case study.

Authors:  C Patriarca; M Roncalli; G Viale; R M Alfano; P Braidotti; F Guddo; G Coggi
Journal:  Histochemistry       Date:  1994-08

5.  Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C.

Authors:  G Giannelli; G Antonelli; G Fera; S Del Vecchio; E Riva; C Broccia; O Schiraldi; F Dianzani
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

Review 6.  Multistep human hepatocarcinogenesis: correlation of imaging with pathology.

Authors:  Masatoshi Kudo
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

7.  Macro-regenerative nodules in biliary atresia: CT/MRI findings and their pathological relations.

Authors:  Jiun-Lung Liang; Yu-Fan Cheng; Allan-M Concejero; Tung-Liang Huang; Tai-Yi Chen; Leo-Leung-Chit Tsang; Hsin-You Ou
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

8.  Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study.

Authors:  E Caturelli; L Solmi; M Anti; S Fusilli; P Roselli; A Andriulli; F Fornari; C Del Vecchio Blanco; I de Sio
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

9.  Viral hepatitis and hepatocellular carcinoma.

Authors:  Peter P Michielsen; Sven M Francque; Jurgen L van Dongen
Journal:  World J Surg Oncol       Date:  2005-05-20       Impact factor: 2.754

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.